S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

VRTX Vertex Pharmaceuticals Inc

400.51

-1.63 (-0.41%)

Last Updated: 14:30:05

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Vertex Pharmaceuticals Charts.

Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Vertex Pharmaceuticals Charts.

Vertex Pharmaceuticals Inc / Ma News

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
Friday 26 April 2024 (6 days ago) • Business Wire

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Monday 22 April 2024 (1 week ago) • PR Newswire (US)

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Thursday 18 April 2024 (2 weeks ago) • Business Wire

Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News
Thursday 11 April 2024 (3 weeks ago) • IH Market News

Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Wednesday 10 April 2024 (3 weeks ago) • Business Wire

Vertex to Announce First Quarter 2024 Financial Results on May 6
Tuesday 9 April 2024 (3 weeks ago) • Business Wire

Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Monday 1 April 2024 (1 month ago) • PR Newswire (Canada)

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Monday 1 April 2024 (1 month ago) • Business Wire

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Thursday 21 March 2024 (1 month ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

More Vertex Pharmaceuticals Inc / Ma News Articles

Atacama Resources (PK)

MicroCloud Hologram

Verb Technology

BlackStar Enterprise (PK)

Mullen Automotive

International Star (PK)

Globestar Therapeutics (PK)

Seven Arts Entertainment (PK)

Buildablock (PK)

Brookmount Explorations (PK)

FBEC Worldwide (PK)

Virexit Technologies (PK)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions